Post-earnings recap
Reported
Thu, May 3, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss of $0.63 per share for the first quarter of 2018, with no revenue reported. The stock reacted negatively, dropping 2.79%, indicating investor concern over the company's financial performance. Without additional commentary or guidance from management, it's difficult to assess future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.63 | N/A | — |
| Revenue | $— | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.